by Demand for Polypill Products to Scale New Heights as Studies Focus on Reducing Side Effects
The healthcare sector worldwide continues to embrace new medical treatments, therapies, and drugs. At present, cardiovascular diseases are considered to be the leading causes of death worldwide due to which, research and development activities pertaining to the treatment of an array of cardiovascular diseases have gained considerable momentum. Although international guidelines advocate the adoption of statins, aspirin, and pressure-lowering therapy for individuals with a history of cardiovascular condition, the adoption of these medications is relatively low. Multiple clinical trials have revealed that the combination of these medications with a polypill product is likely to improve systolic blood pressure, adherence, and low-density lipoprotein cholesterol.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111876
Although the demand for polypill products is expected to witness steady growth during the forecast period, mounting safety concerns surrounding the use of polypill products could hamper its adoption. Research and development activities within the polypill products market are largely focused on minimizing the side effects and investigating the consequences of non-adherence to polypill products in comparison with individual medication. Thus, due to a surge in the prevalence of chronic diseases across the world, the demand for polypill products is projected to witness notable growth in the coming years. At the back of these factors, the global polypill products market is expected to reach market value of ~US$ 35 Bn by the end of 2027.
Efforts to Improve Medication Adherence to Increase Demand for Polypill Products
High cholesterol and high blood pressure are some of the leading causes of cardiovascular deaths worldwide. Although there are treatments and medications available to address these conditions, they are left undertreated particularly in the underdeveloped and developing regions. The lack of adequate prescription and poor medication adherence are some of the leading factors as to why high cholesterol and high blood pressure are undertreated across the world. One of the potential methods to enhance medication adherence that is currently being investigated is the combination of one or more medications into a polypill.
Get a glimpse of the in-depth analysis through our Report Brochure
Some of the major factors that are likely to boost the adoption of polypill products during the forecast period include lower dosage of different medications, which, in turn are projected to reduce the side effects. In addition, players operating in the current polypill products market are expected to advertise polypill products as an easy to remember medication and convenience as the USP to improve their sales. In addition, polypill products have also emerged as a cost-effective medication alternative and likely to replace therapies that require multiple medications.
Despite factors that are likely to increase the demand for polypill products in the coming years, the potential side-effects, overtreatment, undesirable interaction of different medication, and low dosing flexibility are some of the factors that could hinder the demand.
Advent of 3D Printed Drugs to Boost Polypill Products Market
Novel technologies such as 3D printing have played a key role in revolutionizing manufacturing processes in various industries, including automotive, aerospace, and dental. The narrative stands true within the healthcare sector wherein 3D printing is gradually making its mark. Most recently, 3D printing is increasingly being used to develop personalized drugs with improved reliability. The exceptional capability of 3D printing to develop medication with high degree of precision particularly in tune with the requirement of patients is expected to increase the adoption of 3D printing in the polypill products market. Several pharmaceutical companies are inclined toward adopting 3D printing medicines with different drug compounds such as polypills. The growing awareness regarding the benefits of 3D printed medicines is likely to influence the demand for 3D printed polypill products in the coming years.
While new technologies continue to make inroads in the healthcare sector, research and development activities will continue to accelerate the development of new polypill products. Several studies within the polypill products market aim toward the discovery of new polypill products and the potential benefits of the same. For instance, a recent study that is published in the New England Journal of Medicine reveals that polypill products have significant potential in lowering cholesterol and blood pressure among individuals suffering from cardiovascular problems.
Analysts’ Viewpoint
The global polypill products market is expected to grow at a sluggish CAGR of ~2% during the forecast period. Some of the leading factors that are expected to contribute to market growth include a high prevalence of cardiovascular diseases worldwide, gradual adoption of new technologies, including 3D printing to develop polypill products, lower medication cost compared to multiple medications, and research & development activities. Companies operating in the current market landscape should focus on research and development to improve the efficacy of polypill products and simultaneously lower the development costs. The advent of the 3D printing technology could open up new avenues for players in the polypill products market in the coming years.
Polypill Products Market: Overview
The global polypill products market for the historical period 2017–2018 and forecast period 2019–2027, high incidence and prevalence of chronic diseases such as cardiovascular and diabetes mellitus boost the growth of the global polypill products market. Moreover, low cost of products is projected to drive the global polypill products market during the forecast period.
According to the report, the global polypill products market was valued at US$ 29.7 Bn in 2018 and is anticipated to expand at a CAGR of ~2% from 2019 to 2027
Rise in Prevalence of Chronic Diseases and Increase in Focus on R&D: Key Drivers
Sedentary lifestyle and unhealthy diet have increased the prevalence and incidence of chronic diseases. According to the American Heart Association, cardiovascular diseases is the leading cause of death across the globe. According to the World Health Organization (WHO), cardiovascular diseases accounted for an estimated 17.9 million deaths across the world in 2016. This number is expected to increase to 23.6 million by 2030.
Increase in the global geriatric population, which is more prone to chronic diseases, is expected to drive the growth of the global polypill products market. According to the Global Burden of Cardiovascular Diseases (2015), the prevalence of stroke increases above 40 years of age.
Combination of multiple drugs in one dosage form, high adherence among the elderly population, and rise in utilization of polypill products are the major advantages offered by polypill products over other formulations
The factors mentioned above drive the demand for new polypill products. Industry players are investing in research & development to develop and introduce new polypill products to address the need and demand, which in turn is likely to augment the global polypill products market.
Low Cost and Patient Compliance Propel Polypill Products Market
Polypill is a fixed dose combination used in the treatment of various chronic diseases. This combination pharmacotherapy offers the potential to decrease the incidence and prevalence of cardiovascular and other diseases.
Cost of product and treatment is a major factor that influences the selection of treatment. Therefore, low cost of polypill products is boosting adoption.
Patent Expiry and Introduction of Generic Products to Hamper Polypill Products Market
Launch of new generic polypill products hampers the global polypill products market. In May 2017, the U.S. Food and Drug Administration approved a generic version of the anti-cholesterol drug Vytorin.
A number of products will go off patent in the U.S. and Europe in 2021, 2022, and 2025. Patent expiry of products affects market revenue, which in turn is likely to restrain the global polypill products market.
Polypill Products Market: Competition Landscape
This report profiles major players in the global polypill products market based on various attributes and recent developments
The global polypill products market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global polypill products market are
- Pfizer, Inc.
- AstraZeneca
- Merck & Co., Inc. (Merck Sharp & Dohme Corp)
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Dr. Reddy’s Laboratories Ltd.
- Cipla, Inc.
- Cadila Pharmaceuticals
- Grupo Ferrer International,
- S.A
- Gebro Pharma GmbH
- Gilead Sciences, Inc.
- Takeda Pharmaceutical Company Limited
Key Questions Answered in Polypill Products Market Report
- What is the scope of growth for product companies in the global polypill products market?
- What will be the Y-o-Y growth of the global polypill products market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global polypill products market?
- Will North America continue to be the most profitable market for polypill products?
- Which factors are anticipated to hamper the growth of the global polypill products market during the forecast period?
- Which are the leading companies in the global polypill products market?
Polypill Products Market – Segmentation
Application
- Cardiovascular
- Diabetes Mellitus
- Anti-infective
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111876/2900
